Nina Karaseva

8.7k total citations · 1 hit paper
20 papers, 1.3k citations indexed

About

Nina Karaseva is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Nina Karaseva has authored 20 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Nina Karaseva's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). Nina Karaseva is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). Nina Karaseva collaborates with scholars based in Russia, United States and South Korea. Nina Karaseva's co-authors include Mark A. Socinski, Paul Bhar, Igor Bondarenko, Vera Hirsh, Jeremy K. Hon, Ihor Vynnychenko, J. L. Mesías Iglesias, Anatoly Makhson, Isamu Okamoto and Hui Zhang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Nina Karaseva

19 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

2012 592 citations Mark A. Socinski, Igor Bondarenko et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Nina Karaseva

Since Specialization

Citations

This map shows the geographic impact of Nina Karaseva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nina Karaseva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nina Karaseva more than expected).

Fields of papers citing papers by Nina Karaseva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nina Karaseva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nina Karaseva. The network helps show where Nina Karaseva may publish in the future.

Co-authorship network of co-authors of Nina Karaseva

This figure shows the co-authorship network connecting the top 25 collaborators of Nina Karaseva. A scholar is included among the top collaborators of Nina Karaseva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nina Karaseva. Nina Karaseva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA3 Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer 2024 ·Annals of Oncology ·Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz, Takashi Oshima, Nina Karaseva, M. A. Osipov, (unknown), Hiroshi Yabusaki, S. G. Afanasyev, Park Yk, S-E. Al-Batran, Takaki Yoshikawa, (unknown), Maria Di Bartolomeo, Sara Lonardi, (unknown), (unknown), (unknown), Y-J. Bang	7
2	LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study 2023 ·Annals of Oncology ·Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz, Takashi Oshima, Nina Karaseva, M. A. Osipov, Hisateru Yasui, Hiroshi Yabusaki, S. G. Afanasyev, Park Yk, S-E. Al-Batran, Takaki Yoshikawa, (unknown), Maria Di Bartolomeo, Sara Lonardi, (unknown), (unknown), Pooja Bhagia, Y-J. Bang	22
3	Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial. 2022 ·Journal of Clinical Oncology ·Zev A. Wainberg, Kohei Shitara, Eric Van Cutsem, Lucjan Wyrwicz, Keun Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, (unknown), Wasat Mansoor, Maria Ignez Braghiroli, Nina Karaseva, Eray Goekkurt, Hironaga Satake, Joseph Chao, Uma Kher, Sukrut Shah, Pooja Bhagia, Josep Tabernero	17
4	Limitations and opportunities of cancer treatment in the COVID-19 pandemic 2021 ·SHILAP Revista de lepidopterología ·Р. В. Орлова, (unknown), Анна Малкова, (unknown), (unknown), (unknown), (unknown), (unknown), Nina Karaseva, (unknown), (unknown), (unknown)	0
5	Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study 2021 ·ESMO Open ·David Planchard, Po‐Hao Feng, Nina Karaseva, (unknown), (unknown), Chee Khoon Lee, Artem Poltoratskiy, Noriko Yanagitani, (unknown), (unknown), Paul Howarth, Pasi A. Jänne, Kunihiko Kobayashi	51
6	1401P Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study 2020 ·Annals of Oncology ·David Planchard, (unknown), Nina Karaseva, S-W. Kim, (unknown), Chee Khoon Lee, Artem Poltoratskiy, Noriko Yanagitani, (unknown), Xiaoyan Huang, Paul Howarth, Pasi A. Jänne, Kunihiko Kobayashi	7
7	Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial 2020 ·Annals of Oncology ·Aaron S. Mansfield, Andrzej Każarnowicz, Nina Karaseva, (unknown), Richard de Boer, Zoran Andrić, Martin Reck, Shinji Atagi, Jae‐Seong Lee, Marina Chiara Garassino, Stephen V. Liu, Leora Horn, Xiaoming Wen, Caroleen Quach, Weiguang Yu, Fairooz F. Kabbinavar, Sivuonthanh Lam, S. Morris, Raffaele Califano	126
8	Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer 2019 ·European Journal of Cancer ·Natasha B. Leighl, Nina Karaseva, Kazuhiko Nakagawa, Byoung Chul Cho, Jhanelle E. Gray, (unknown), Andrew Walding, Anna Rydén, Silvia Novello	46
9	An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer 2019 ·Lung Cancer ·Daniel Morgensztern, Nina Karaseva, Enriqueta Felip, Ignacio Delgado, Olga Burdaeva, Manuel Dómine, Primo N. Lara, Paul K. Paik, Ulrik Lassen, С. В. Орлов, José Trigo, (unknown), Katherine L. Baker-Neblett, (unknown), Xiaowei Wang, Yan Li, Ionel Mitrica, M. Phillip DeYoung, Pilar Garrido	19
10	Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants 2018 ·Biochimie ·Natalia V. Mitiushkina, (unknown), Aglaya G. Iyevleva, Maksim Kholmatov, Е. А. Филиппова, Fedor V. Moiseyenko, (unknown), (unknown), (unknown), (unknown), Nikita Volkov, Nina Karaseva, Vladimir Moiseyenko, С. В. Орлов, Evgeny N. Imyanitov	11
11	139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) 2018 ·Journal of Thoracic Oncology ·Natasha B. Leighl, Nina Karaseva, Ken Nakagawa, (unknown), Jhanelle E. Gray, (unknown), Andrew Walding, Anna Rydén, Silvia Novello	6
12	Lung cancers carrying distinct ALK fusion variants demonstrate similar responsiveness to ALK tyrosine kinase inhibitors 2018 ·Annals of Oncology ·Evgeny N. Imyanitov, (unknown), (unknown), Aglaya G. Iyevleva, (unknown), Elena V. Filippova, Fedor V. Moiseyenko, (unknown), (unknown), (unknown), Alexandr V. Togo, Nina Karaseva, Vladimir Moiseyenko, Sergey Orlov	1
13	Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial 2017 ·Clinical Lung Cancer ·Suresh S. Ramalingam, M. Pérol, Martin Reck, Rubén Dario Kowalyszyn, Oliver Gautschi, Martin Kimmich, Eun Kyung Cho, Grzegorz Czyżewicz, Alexandru Grigorescu, Nina Karaseva, Shaker R. Dakhil, Pablo Lee, (unknown), Andreas Sashegyi, Ekaterine Alexandris, Gebra Cuyún Carter, Katherine B. Winfree, Edward B. Garon	6
14	Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial 2012 ·Journal of Clinical Oncology ·Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczęsna, János Strausz, А. Н. Махсон, Martin Reck, Rafal Wierzbicki, István Albert, Michael Thomas, José Elias Miziara, Zsolt Pápai, Nina Karaseva, Sumitra Thongprasert, E. Dalmau, Joachim von Pawel, Ke Zhang, Paulina Selaru, L. Tye, Richard C. Chao, Ramaswamy Govindan	174
15	Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial breakdown → 2012 ·Journal of Clinical Oncology ·Mark A. Socinski, Igor Bondarenko, Nina Karaseva, Anatoly Makhson, Ihor Vynnychenko, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Paul Bhar, Hui Zhang, J. L. Mesías Iglesias, Markus F. Renschler	592
16	Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer 2011 ·Journal of Thoracic Oncology ·Neal Ready, Nina Karaseva, С. В. Орлов, Alexander Luft, (unknown), Jon Holmlund, Brian Wood, Lance Leopold	74
17	Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. 2011 ·Journal of Clinical Oncology ·Mark A. Socinski, Igor Bondarenko, Nina Karaseva, А. Н. Махсон, Ihor Vynnychenko, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Paul Bhar, (unknown), J. L. Mesías Iglesias	5
18	Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). 2010 ·Journal of Clinical Oncology ·Mark A. Socinski, Igor Bondarenko, Nina Karaseva, А. Н. Махсон, (unknown), Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Paul Bhar, José Iglesias	15
19	Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer 2009 ·Journal of Clinical Oncology ·Mark A. Socinski, Egbert F. Smit, Paul Lorigan, Kartik Konduri, Martin Reck, Aleksandra Szczęsna, Johnetta Blakely, Piotr Serwatowski, Nina Karaseva, Tudor–Eliade Ciuleanu, Jacek Jassem, Mircea Dediu, Shengyan Hong, Carla Visseren‐Grul, (unknown), Coleman K. Obasaju, Susan C. Guba, Nick Thatcher	159
20	Prognostic value of non-MHC-restricted killer cell activity in lung cancer 1993 ·Cancer Immunology Immunotherapy ·(unknown), (unknown), (unknown), Nina Karaseva, (unknown), Tuomo Timonen	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact